+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Pancreatic Cancer

  • ID: 4775094
  • Report
  • February 2021
  • Region: Global
  • 60 Pages
  • Pharma Intelligence
This Market Spotlight report covers the Pancreatic Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The publisher estimates that in 2019, there were 462,100 incident cases of pancreatic cancer worldwide, and expects that number to increase to 486,300 incident cases by 2028.
  • The approved drugs in the pancreatic cancer space target microtubules (tubulin), DNA, DNA synthesis, topoisomerase I, poly ADP-ribose polymerase, dihydropyrimidine dehydrogenase, thymidylate synthase, and epidermal growth factor receptor. These drugs are commonly administered via the intravenous route, with a few select products being available in oral and intratumoral formulations.
  • The majority of industry-sponsored drugs in active clinical development for pancreatic cancer are in Phase II. Therapies in development for pancreatic cancer focus on a wide variety of targets. The majority of pipeline drugs for pancreatic cancer are administered via the oral or intravenous routes.
  • High-impact upcoming events for drugs in the pancreatic cancer space comprise topline Phase II/III, Phase II, and Phase III trial results, and an expected patent expiration.
  • The overall likelihood of approval of a Phase I pancreatic cancer asset is 2%, and the average probability a drug advances from Phase III is 13.8%. Drugs, on average, take 10.7 years from Phase I to approval, compared to 9.5 years in the overall oncology space.
  • The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for pancreatic cancer have been in the early and mid-phases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
  • The US has a substantial lead in the number of pancreatic cancer clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the pancreatic cancer space is dominated by completed trials. Roche has the highest number of completed clinical trials for pancreatic cancer, with 103 trials.
  • Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for pancreatic cancer, followed by Roche
Note: Product cover images may vary from those shown

OVERVIEWKEY TAKEAWAYS
DISEASE BACKGROUND
  • Subtypes

TREATMENT
  • Surgery
  • Ablation or embolization
  • Radiation therapy
  • Chemotherapy
  • Targeted therapy
  • Immunotherapy
  • Drugs used specifically for the treatment of PNETs

EPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
  • Motixafortide for Pancreatic Cancer (January 24, 2020)
  • Lynparza for Pancreatic Cancer (December 17, 2019)
  • Pegilodecakin for Pancreatic Cancer (October 16, 2019)
  • Acelarin for Pancreatic Cancer (August 20, 2019)
  • Mavorixafor for Pancreatic Cancer (July 17, 2019)
  • Napabucasin for Pancreatic Cancer (July 1, 2019)
  • Abraxane for Pancreatic Cancer (June 2, 2019)
  • Lynparza for Pancreatic Cancer (June 2, 2019)
  • NanoKnife System for Pancreatic Cancer (May 13, 2019)
  • MVT-5873 for Pancreatic Cancer (May 8, 2019)

KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
  • Lynparza Gets US OK For Pancreatic Cancer

PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
  • Cytocom Goes Public Via Merger With Cleveland BioLabs
  • Exact Goes All-In On Multi-Cancer Screening With $2.15Bn For Thrive; $410M For Base Genomics
  • TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens
  • Processa Licenses IP For Next-Generation Irinotecan From Aposense
  • Bristol Myers Squibb declines to exercise Agios Pharmaceuticals opt-in right for AG-270
  • DeMelle Licenses Pancreatic Cancer Candidate From Moffit
  • Taiho Acquires Asian Rights To Arcus IO Candidate
  • Tyme, Eagle Collaborate On Development Of Pancreatic Cancer Drug
  • Astellas Taps Pandion In Pancreas Immunomodulator Deal

REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY
  • Prescription information

APPENDIX
LIST OF FIGURES
Figure 1: Trends in incident cases of pancreatic cancer, 2019–28
Figure 2: Overview of pipeline drugs for pancreatic cancer in the US
Figure 3: Pipeline drugs for pancreatic cancer, by company
Figure 4: Pipeline drugs for pancreatic cancer, by drug type
Figure 5: Pipeline drugs for pancreatic cancer, by classification
Figure 6: Motixafortide for Pancreatic Cancer (January 24, 2020): Phase Ib/II - w/Atezolizumab
Figure 7: Pegilodecakin for Pancreatic Cancer (October 16, 2019): Phase III - SEQUOIA (w/FOLFOX)
Figure 8: Lynparza for Pancreatic Cancer (June 2, 2019): Phase III - POLO
Figure 9: Key upcoming events in pancreatic cancer
Figure 10: Probability of success in the pancreatic cancer pipeline
Figure 11: Clinical trials in pancreatic cancer
Figure 12: Top 10 drugs for clinical trials in pancreatic cancer
Figure 13: Top 10 companies for clinical trials in pancreatic cancer
Figure 14: Trial locations in pancreatic cancer
Figure 15: Pancreatic cancer trials status
Figure 16: Pancreatic cancer trials sponsors, by phase
LIST OF TABLES
Table 1: Incident cases of pancreatic cancer, 2019–28
Table 2: Marketed drugs for pancreatic cancer
Table 3: Pipeline drugs for pancreatic cancer in the US
Table 4: Motixafortide for Pancreatic Cancer (January 24, 2020)
Table 5: Lynparza for Pancreatic Cancer (December 17, 2019)
Table 6: Pegilodecakin for Pancreatic Cancer (October 16, 2019)
Table 7: Acelarin for Pancreatic Cancer (August 20, 2019)
Table 8: Mavorixafor for Pancreatic Cancer (July 17, 2019)
Table 9: Napabucasin for Pancreatic Cancer (July 1, 2019)
Table 10: Abraxane for Pancreatic Cancer (June 2, 2019)
Table 11: Lynparza for Pancreatic Cancer (June 2, 2019)
Table 12: NanoKnife System for Pancreatic Cancer (May 13, 2019)
Table 13: MVT-5873 for Pancreatic Cancer (May 8, 2019)
Table 14: Historical global sales, by drug ($m), 2015–19
Table 15: Forecasted global sales, by drug ($m), 2020–24
Note: Product cover images may vary from those shown